Cardiovascular Phase 3 Deal Benchmarks — Japan

Understanding Cardiovascular Deal Benchmarks at Phase 3

Phase 3 Cardiovascular licensing deals in Japan territory command a median upfront payment of $124M, with values ranging from $80M at the low end to $178M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the cardiovascular therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $299M to $499M, with a median of $399M. Royalty rates for cardiovascular assets at this stage typically fall between 6.4% and 11.8% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Japan territory applies a 0.09x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating japan rights should calibrate upfront expectations and milestone structures accordingly.